HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
Wall Street Journal24d
Vertex Corp.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
McKesson, Vertex Pharmaceuticals among top healthcare Quant picks before Q4 earnings
The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...
Vertex, Inc. (NASDAQ:VERX) Given Average Rating of “Moderate Buy” by Brokerages
Vertex, Inc. (NASDAQ:VERX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, MarketBeat.com reports. Four ...
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...
Nasdaq1mon
Channel Therapeutics Corporation Comments on Vertex Pharmaceuticals' Phase 2 Data for NaV1.8 Inhibitor and Outlines NaV1.7 Therapeutic Approach
Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...
ETF Daily News28d
M&T Bank Corp Lowers Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
M&T Bank Corp trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 18,867 ...